These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 14985771)

  • 21. All together now?
    Nat Biotechnol; 2006 Dec; 24(12):1454. PubMed ID: 17160026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chasing biotech, state by state--winners and losers.
    Wilan KH
    Nat Biotechnol; 2005 Feb; 23(2):175-9. PubMed ID: 15696143
    [No Abstract]   [Full Text] [Related]  

  • 23. Biotech boom prompts fears of bust.
    Ledford H
    Nature; 2013 Aug; 500(7464):513. PubMed ID: 23985852
    [No Abstract]   [Full Text] [Related]  

  • 24. Young scientists ditch postdocs for biotech start-ups.
    Check Hayden E
    Nature; 2016 Nov; 539(7627):14-15. PubMed ID: 27808219
    [No Abstract]   [Full Text] [Related]  

  • 25. Japanese giants renew interest in industrial biotech.
    Sipp D
    Nat Biotechnol; 2005 Mar; 23(3):275-6. PubMed ID: 15765071
    [No Abstract]   [Full Text] [Related]  

  • 26. Costa Rica's biotech project still on track for end of year.
    Corrales A
    Nature; 2008 May; 453(7195):586. PubMed ID: 18509417
    [No Abstract]   [Full Text] [Related]  

  • 27. Japanese firms broaden investment focus to early biotech.
    Louët S; Sipp D
    Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
    [No Abstract]   [Full Text] [Related]  

  • 28. Evolving paradigms in biotech IPO valuations.
    Papadopoulos S
    Nat Biotechnol; 2001 Jul; 19 Suppl():BE18-9. PubMed ID: 11433243
    [No Abstract]   [Full Text] [Related]  

  • 29. Early-stage returns?
    Booth BL
    Nat Biotechnol; 2006 Nov; 24(11):1335-40. PubMed ID: 17093473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trust me, I'm a doctor.
    Smaglik P
    Nature; 2003 Nov; 426(6962):101. PubMed ID: 14603327
    [No Abstract]   [Full Text] [Related]  

  • 31. Delisting threat looms large on biotech front.
    Lawrence S
    Nat Biotechnol; 2005 Jan; 23(1):5. PubMed ID: 15637598
    [No Abstract]   [Full Text] [Related]  

  • 32. Nasdaq dilutes its biotech index.
    Dorey E
    Nat Biotechnol; 2004 Jan; 22(1):9. PubMed ID: 14704690
    [No Abstract]   [Full Text] [Related]  

  • 33. Paring down the company: the effect of consolidation in the European biotech sector.
    Bassett P
    Nat Biotechnol; 2003 Jul; 21(7):829-30. PubMed ID: 12833105
    [No Abstract]   [Full Text] [Related]  

  • 34. Mind the (biomedical funding) gap.
    Klausner A
    Nat Biotechnol; 2005 Oct; 23(10):1217-8. PubMed ID: 16211055
    [No Abstract]   [Full Text] [Related]  

  • 35. What's hot in biotech employment.
    Hochberg SP
    Nat Biotechnol; 2001 Apr; 19(4):389. PubMed ID: 11283604
    [No Abstract]   [Full Text] [Related]  

  • 36. PEGging biotech growth.
    Jacobs T
    Nat Biotechnol; 2006 May; 24(5):506. PubMed ID: 16680127
    [No Abstract]   [Full Text] [Related]  

  • 37. The number on biotech indexes.
    Jacobs T
    Nat Biotechnol; 2005 Nov; 23(11):1356. PubMed ID: 16273059
    [No Abstract]   [Full Text] [Related]  

  • 38. Biotech marks time in Q3.
    Lawrence S
    Nat Biotechnol; 2005 Nov; 23(11):1332. PubMed ID: 16273049
    [No Abstract]   [Full Text] [Related]  

  • 39. IPO plans sour on both sides of the pond.
    Mitchell P
    Nat Biotechnol; 2004 Aug; 22(8):929-30. PubMed ID: 15286629
    [No Abstract]   [Full Text] [Related]  

  • 40. Tough times set to continue for US biotech start-ups.
    Lehrman S
    Nature; 1999 Jan; 397(6716):191. PubMed ID: 9930684
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.